|
News FDA Approves Baxter`s ADVATE as the Only FVIII for Routine Prophylaxis in Both Adults and Children with Hemophilia A
Baxter International Inc. announced that the U.S. Food and Drug Administration (FDA) has approved ADVATE [Antihemophilic Factor (Recombinant) Plasma/Albumin Free Method] for routine prophylaxis to prevent or reduce the frequency of bleeding episodes in patients with hemophilia A. |